WO2008084402A8 - Diagnosis and treatment of alzheimer's and other neurodementing diseases - Google Patents
Diagnosis and treatment of alzheimer's and other neurodementing diseases Download PDFInfo
- Publication number
- WO2008084402A8 WO2008084402A8 PCT/IB2008/000456 IB2008000456W WO2008084402A8 WO 2008084402 A8 WO2008084402 A8 WO 2008084402A8 IB 2008000456 W IB2008000456 W IB 2008000456W WO 2008084402 A8 WO2008084402 A8 WO 2008084402A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alzheimer
- treatment
- antibodies
- neurodementing
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK08719192.0T DK2104682T3 (en) | 2007-01-11 | 2008-01-11 | DIAGNOSIS AND TREATMENT OF ALZHEIMER'S AND OTHER DEMENTIA DISEASES |
EP08719192.0A EP2104682B1 (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
AU2008204335A AU2008204335B2 (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of Alzheimer's and other neurodementing diseases |
JP2009545252A JP2010515717A (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of Alzheimer and other neurodementia disorders |
CA2675340A CA2675340C (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
ES08719192.0T ES2610474T3 (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of Alzheimer's disease and other neurodegenerative diseases causing dementia |
SI200831731A SI2104682T1 (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
Applications Claiming Priority (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88451307P | 2007-01-11 | 2007-01-11 | |
US88452607P | 2007-01-11 | 2007-01-11 | |
EP07000507.9 | 2007-01-11 | ||
EP07000521A EP1944315A1 (en) | 2007-01-11 | 2007-01-11 | Prophylaxis and therapy of alzheimer's disease and other neurodementing diseases |
EP07000507A EP1944314A1 (en) | 2007-01-11 | 2007-01-11 | Diagnosis of Alzheimer's disease and other neurodementing disorders |
US60/884,526 | 2007-01-11 | ||
US60/884,513 | 2007-01-11 | ||
EP07000521.0 | 2007-01-11 | ||
US98166707P | 2007-10-22 | 2007-10-22 | |
US98167507P | 2007-10-22 | 2007-10-22 | |
EP07119026.8 | 2007-10-22 | ||
US60/981,667 | 2007-10-22 | ||
EP07119002 | 2007-10-22 | ||
EP07119002.9 | 2007-10-22 | ||
EP07119026 | 2007-10-22 | ||
US60/981,675 | 2007-10-22 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008084402A2 WO2008084402A2 (en) | 2008-07-17 |
WO2008084402A3 WO2008084402A3 (en) | 2009-04-09 |
WO2008084402A8 true WO2008084402A8 (en) | 2009-08-27 |
Family
ID=39609117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/000456 WO2008084402A2 (en) | 2007-01-11 | 2008-01-11 | Diagnosis and treatment of alzheimer's and other neurodementing diseases |
Country Status (11)
Country | Link |
---|---|
US (3) | US7939075B2 (en) |
EP (1) | EP2104682B1 (en) |
JP (1) | JP2010515717A (en) |
AU (1) | AU2008204335B2 (en) |
CA (1) | CA2675340C (en) |
DK (1) | DK2104682T3 (en) |
ES (1) | ES2610474T3 (en) |
PL (1) | PL2104682T3 (en) |
SI (1) | SI2104682T1 (en) |
TW (1) | TW200844110A (en) |
WO (1) | WO2008084402A2 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090280114A1 (en) * | 2002-04-12 | 2009-11-12 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
KR101439828B1 (en) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | Monoclonal antibodies against amyloid beta protein and uses thereof |
AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
EP2143447A1 (en) * | 2008-07-11 | 2010-01-13 | Universität Konstanz | Bioconjugates comprising Aß-autoantibody-specific epitopes for active immunotherapy and diagnosis of Alzheimer's disease |
TR201908314T4 (en) * | 2009-02-20 | 2019-06-21 | 2 Bbb Medicines B V | Glutathione based drug delivery system. |
KR101095630B1 (en) * | 2009-06-17 | 2011-12-19 | 주식회사 이노파마스크린 | A method for screening a compound of inhibiting interaction between beta-amyloid and VEGF and beta-amyloid inhibitor thereof |
DE102009034119A1 (en) * | 2009-07-20 | 2011-01-27 | Philipps-Universität Marburg | Method, in particular enzyme-linked immunosorbent assay (ELISA), for in vitro detection of amyloid beta autoantibodies, microtiter plate and test kit |
EP2921486B1 (en) | 2009-08-07 | 2017-09-27 | American Life Science Pharmaceuticals, Inc. | Compositions and methods for treating beta-amyloid related diseases |
CA2796339C (en) | 2010-04-15 | 2020-03-31 | Abbott Laboratories | Amyloid-beta binding proteins |
EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
SI2579042T1 (en) * | 2011-10-04 | 2014-09-30 | Affiris Ag | Method for detecting Ass-specific antibodies in a biological sample |
KR101190573B1 (en) * | 2011-10-07 | 2012-10-18 | 대한민국 | THE NOVEL A ß 22(pE)-42 PEPTIDE THAT BIND TO AMYLOID-BETA ANTIBODY SPECIFICALLY IN BLOOD AND PHARMACEUTICALLY COMPOSITION FOR THE DIAGNOSIS OF DEMENTIA DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT |
CN104662423A (en) * | 2012-03-13 | 2015-05-27 | 杨森阿尔茨海默氏症免疫治疗公司 | Oligomeric Abeta in the diagnosis, prognosis, and monitoring of alzheimer's disease |
AU2013203043B2 (en) * | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
JP6582995B2 (en) * | 2014-01-21 | 2019-10-02 | 株式会社島津製作所 | Method for measuring APP-cleaved peptide |
WO2016054114A1 (en) | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions |
ES2663623T3 (en) * | 2015-01-12 | 2018-04-16 | Heraeus Deutschland GmbH & Co. KG | Use of an electrically conductive composition as an electrically conductive adhesive to mechanically and electrically connect electrical conductors with the solar cell electrical contacts |
ES2834484T3 (en) | 2016-11-21 | 2021-06-17 | Univ Ruhr Bochum | Method for preselection of drugs for protein misfolding diseases |
EP3728323A4 (en) * | 2017-12-19 | 2022-01-26 | Surrozen Operating, Inc. | Anti-frizzled antibodies and methods of use |
AU2018393076A1 (en) | 2017-12-19 | 2020-07-02 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
JP7330977B2 (en) * | 2017-12-19 | 2023-08-22 | スロゼン オペレーティング, インコーポレイテッド | Wnt surrogate molecules and uses thereof |
TW202300517A (en) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | Anti-amyloid beta antibodies and uses thereof |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
DE68925971T2 (en) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
JPH07501451A (en) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | Multivalent antigen binding protein |
DE69432629T3 (en) * | 1993-01-25 | 2008-01-17 | Takeda Pharmaceutical Co. Ltd. | ANTIBODIES AGAINST BETA AMYLOID OR DERIVATIVES AND ITS USE |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
ATE402717T1 (en) | 1997-04-09 | 2008-08-15 | Intellect Neurosciences Inc | RECOMBINANT ANTIBODIES SPECIFIC TO BETA-AMYLOID TERMS, DNA CODING THEREFOR, AND METHOD FOR USE THEREOF |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
DE19926068C1 (en) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteins of the bilin binding protein |
CA2393763A1 (en) | 1999-12-08 | 2001-06-14 | Mindset Biopharmaceuticals (Usa), Inc. | Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
US20020182660A1 (en) | 2000-02-18 | 2002-12-05 | Fong Kei-Lai L. | N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43) |
US20030083277A1 (en) | 2000-02-24 | 2003-05-01 | Hersh Louis B. | Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients |
TR200202799T3 (en) | 2000-02-24 | 2003-03-21 | Washington University St.Louis | Humanized antibodies that sequence the AB peptide |
PT2275449T (en) * | 2000-06-16 | 2016-12-27 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
US20020009445A1 (en) | 2000-07-12 | 2002-01-24 | Yansheng Du | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
EP1172378A1 (en) | 2000-07-12 | 2002-01-16 | Richard Dr. Dodel | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
US6815175B2 (en) | 2001-03-16 | 2004-11-09 | Cornell Research Foundation, Inc. | Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder |
MXPA04000747A (en) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Stable lyophilized pharmaceutical formulation of igg antibodies. |
US20030082191A1 (en) | 2001-08-29 | 2003-05-01 | Poduslo Joseph F. | Treatment for central nervous system disorders |
WO2003040183A2 (en) | 2001-11-09 | 2003-05-15 | The Genetics Company, Inc | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
US20050227941A1 (en) | 2001-12-17 | 2005-10-13 | Karen Duff | Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases |
AR038568A1 (en) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | ANTI-A BETA ANTIBODIES AND ITS USE |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1911765A3 (en) | 2002-07-24 | 2008-04-23 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation |
WO2005025516A2 (en) | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
ATE506072T1 (en) | 2002-09-12 | 2011-05-15 | Univ California | IMMUNOGENIC AND CORRESPONDING ANTIBODIES SPECIFIC TO COMMON HIGH MOLECULAR AGGREGATION INTERMEDIATE PRODUCTS OF AMYLOIDS FROM PROTEINS OF DIFFERENT SEQUENCE |
WO2004031400A2 (en) | 2002-10-01 | 2004-04-15 | Northwestern University | Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
CA2501945A1 (en) | 2002-10-09 | 2004-04-22 | Rinat Neuroscience Corp. | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
US20050106626A1 (en) | 2002-10-20 | 2005-05-19 | George Pieczenik | Ligand binding of amyloid peptide protein epitope |
AU2003295471B2 (en) * | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
US20070010435A1 (en) | 2002-12-19 | 2007-01-11 | New York University | Method for treating amyloid disease |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
UY28641A1 (en) * | 2003-11-28 | 2005-06-30 | Astrazeneca Ab | ANTIBODIES |
EA009872B1 (en) | 2004-02-23 | 2008-04-28 | Эли Лилли Энд Компани | ANTI-Aβ ANTIBODY |
SE0401601D0 (en) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
AU2005271892A1 (en) | 2004-07-10 | 2006-02-16 | Alexion Pharmaceuticals, Inc. | Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby |
WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
US20080044356A1 (en) | 2004-10-22 | 2008-02-21 | Regents Of The University Of Minnesota | Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
WO2006055178A2 (en) | 2004-10-25 | 2006-05-26 | Merck & Co., Inc. | Anti-addl antibodies and uses thereof |
PE20061401A1 (en) * | 2004-12-15 | 2006-12-23 | Neuralab Ltd | Aß ANTIBODIES TO IMPROVE COGNITION |
AU2005319382B2 (en) * | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
WO2006081171A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
RU2007124933A (en) | 2005-01-28 | 2009-03-10 | Вайет (Us) | STABILIZED LIQUID POLYPEPTIDE COMPOSITIONS |
AU2006222193B2 (en) | 2005-03-05 | 2011-11-17 | AbbVie Deutschland GmbH & Co. KG | Screening method, process for purifying of non-diffusible A-beta oligomers, selective antibodies against said non-diffusible A-beta oligomers and a process for manufacturing of said antibodies |
ES2318918B1 (en) | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | HUMAN ANTIBODIES WITH CAPACITY OF UNION TO THE BETA-AMYLOID PEPTIDE AND ITS APPLICATIONS. |
MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
CA2630964A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of alzheimer's and related diseases |
KR101439828B1 (en) | 2005-11-30 | 2014-09-17 | 애브비 인코포레이티드 | Monoclonal antibodies against amyloid beta protein and uses thereof |
RU2015111675A (en) | 2005-12-12 | 2015-08-10 | Ац Иммуне Са | SPECIFIC IN RESPECT TO AMYLOID BETA (A BETA) 1-42 MONOCLONAL ANTIBODIES WITH THERAPEUTIC PROPERTIES |
RU2429244C2 (en) | 2006-03-23 | 2011-09-20 | Байоарктик Ньюросайенс Аб | Improved protofibril-selective antibodies and use thereof |
JP2010516651A (en) * | 2007-01-17 | 2010-05-20 | メルク セローノ ソシエテ アノニム | Methods for purification of Fc-containing proteins |
PL2246427T3 (en) * | 2008-02-08 | 2017-06-30 | Immunas Pharma, Inc. | Antibodies capable of binding specifically to amyloid beta-oligomers, and use thereof |
-
2008
- 2008-01-11 WO PCT/IB2008/000456 patent/WO2008084402A2/en active Application Filing
- 2008-01-11 AU AU2008204335A patent/AU2008204335B2/en not_active Ceased
- 2008-01-11 US US12/013,185 patent/US7939075B2/en active Active
- 2008-01-11 PL PL08719192T patent/PL2104682T3/en unknown
- 2008-01-11 EP EP08719192.0A patent/EP2104682B1/en active Active
- 2008-01-11 JP JP2009545252A patent/JP2010515717A/en active Pending
- 2008-01-11 CA CA2675340A patent/CA2675340C/en active Active
- 2008-01-11 SI SI200831731A patent/SI2104682T1/en unknown
- 2008-01-11 DK DK08719192.0T patent/DK2104682T3/en active
- 2008-01-11 TW TW097101288A patent/TW200844110A/en unknown
- 2008-01-11 ES ES08719192.0T patent/ES2610474T3/en active Active
-
2011
- 2011-04-05 US US13/079,886 patent/US20120040382A1/en not_active Abandoned
- 2011-04-05 US US13/079,852 patent/US8491903B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2008204335A1 (en) | 2008-07-17 |
US20090028869A1 (en) | 2009-01-29 |
ES2610474T3 (en) | 2017-04-27 |
EP2104682B1 (en) | 2016-09-21 |
US7939075B2 (en) | 2011-05-10 |
US8491903B2 (en) | 2013-07-23 |
EP2104682A2 (en) | 2009-09-30 |
AU2008204335B2 (en) | 2013-06-13 |
WO2008084402A3 (en) | 2009-04-09 |
SI2104682T1 (en) | 2017-05-31 |
PL2104682T3 (en) | 2017-03-31 |
US20120040382A1 (en) | 2012-02-16 |
CA2675340C (en) | 2018-07-31 |
DK2104682T3 (en) | 2017-01-16 |
US20120039897A1 (en) | 2012-02-16 |
JP2010515717A (en) | 2010-05-13 |
TW200844110A (en) | 2008-11-16 |
CA2675340A1 (en) | 2008-07-17 |
WO2008084402A2 (en) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008084402A8 (en) | Diagnosis and treatment of alzheimer's and other neurodementing diseases | |
EA016193B9 (en) | Antibodies directed against amyloid-beta peptide and methods using same | |
MX2009003468A (en) | Antibodies. | |
WO2008060364A3 (en) | Humani zed antibody against amyloid beta | |
MX2009013503A (en) | Monoclonal anti beta amyloid antibody. | |
MX358175B (en) | A beta 1-42 specific monoclonal antibodies with therapeutic properties. | |
WO2008067464A3 (en) | NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES | |
WO2008150946A8 (en) | HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF | |
MX2009007136A (en) | Method of providing disease-specific binding molecules and targets. | |
EP2650308A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
MX2009012950A (en) | Humanized antibodies to aã(20-42) globulomer and uses thereof. | |
UA109633C2 (en) | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
EP2987807A3 (en) | Antibodies recognising phospho-tau | |
WO2009149486A3 (en) | Compounds for treating beta-amyloidoses | |
WO2002046222A3 (en) | Compositions and methods for diagnosing alzheimer's disease | |
EP2730659A3 (en) | Treatment and Prophylaxis of Amyloidosis | |
MX341369B (en) | Safe and functional humanized anti beta-amyloid antibody. | |
WO2009048539A3 (en) | Use of anti-amyloid beta antibody in ocular diseases | |
WO2009149485A3 (en) | Compounds for treating amyloidoses | |
MX2012014739A (en) | Novel antibody for the diagnosis and/or prognosis of cancer. | |
WO2008042024A3 (en) | Neuroactive fragments of app | |
WO2003040183A3 (en) | Compounds for the diagnosis/prevention/treatment of alzheimer's disease | |
TN2014000458A1 (en) | Anti -transglutaminase 2 antibodies | |
JO3188B1 (en) | Antigen binding proteins specific for serum amyloid p component | |
WO2013063412A3 (en) | Methods of diagnosis and treatment of endoplasmic reticulum (er) stress-related conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08719192 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2009545252 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2675340 Country of ref document: CA Ref document number: 2008204335 Country of ref document: AU Ref document number: MX/A/2009/007450 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008204335 Country of ref document: AU Date of ref document: 20080111 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2008719192 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008719192 Country of ref document: EP |